Protocol Ledger

NCT05415410 · Phase II · TERMINATED

Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

Interventional Phase II clinical trial protocol NCT05415410 sponsored by VectivBio AG in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-25 Enrollment: 31 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05415410
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)31 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05415410
Protocol FieldVerified Registry Value
NCT IdentifierNCT05415410
Consolidated Lead SponsorVectivBio AG
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment31 participants (ACTUAL)
Registered Start Date2022-05-25
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI